Skip to main navigation

Fate Therapeutics

0
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Career Opportunities
    • Vision, Mission, Values
    • Working at Fate
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
    • Investors FAQs

Financials & Filings

ANNUAL REPORTS

Title View
2021 Annual Report 2.1 MB
2021 Annual Report 2.1 MB
2020 Annual Report 1.1 MB
2020 Annual Report 1.1 MB

PROXY STATEMENTS

Filing date View
Apr 25, 2022 View HTML
0001193125-22-117538.pdf
0001193125-22-117538.xls
Apr 21, 2021 View HTML
0001193125-21-124711.pdf
0001193125-21-124711.xls

FORM 10-K

Filing date View
Feb 28, 2023 View HTML
0000950170-23-005067.pdf
0000950170-23-005067.xls
Feb 28, 2022 View HTML
0000950170-22-002293.pdf
0000950170-22-002293.xls

FORM 10-Q

Filing date View
Nov 03, 2022 View HTML
0000950170-22-021840.pdf
0000950170-22-021840.xls
Aug 03, 2022 View HTML
0000950170-22-014236.pdf
0000950170-22-014236.xls

Shareholder Tools

Printed Materials
Email Alerts
Download Library
RSS News Feeds
Print Page
Share
Search

  • Facebook
  • LinkedIn
  • Twitter
  • RSS

© 2023 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL

MENU
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact